ATARA Biotherapeutics (ATRA) Misses Q2 EPS by 10c

ATARA Biotherapeutics (NASDAQ: ATRA) reported Q2 EPS of ($0.32), $0.10 worse than the analyst estimate of ($0.22). Revenue for the quarter came in at $630 thousand versus the consensus estimate of $2.55 million.

For earnings history and earnings-related data on ATARA Biotherapeutics (ATRA) click here.

You May Also Be Interested In

• Is the global equity rally broadening? UBS weighs in
• Hershey (HSY) PT Lowered to $206; RBC Capital: 'Struggling to See a Near Term Positive Inflection'
• Idex Corp. (IEX) Reiterated at Buy by Stifel